Comparing the current results to its competitors, Phoenix Biotech Acquisition reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 12.25 %, recorded in the same quarter.
Phoenix Biotech Acquisition's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical sector, focusing on novel immunotherapies for cancer treatment. It faces competition from large and specialty pharmaceutical, biopharmaceutical, and biotechnology companies, as well as academic, governmental, public, and private research institutions. Competitors differ based on the technologies employed and the development stages of their product candidates. Many smaller biotechnology firms collaborate with larger companies to support research, development, commercialization, or to combine treatment approaches. Specifically, the company competes with developers of TCR T therapies, including Adaptimmune Therapeutics, plc, GlaxoSmithKline plc, MediGene AG, TCR2 Therapeutics Inc., TScan Therapeutics Inc., and Ziopharm Oncology, Inc. Additional competition comes from T cell therapy companies with target discovery platforms such as Adaptive Therapeutics, Inc., Immatics, N.V., and 3T Biosciences, Inc.
Publicly Traded Peers of Phoenix Biotech Acquisition Corp
Crispr Therapeutics Ag Share Performance
+3.76%
This Year
Crispr Therapeutics Ag
Profile
CRISPR Therapeutics AG is a biopharmaceutical company focused on developing transformative gene-based medicines using its CRISPR/Cas9 gene-editing platform. They aim to leverage the potential of CRISPR to treat severe genetic diseases by directly modifying genes within the body's cells. The company collaborates with partners, conducts research and development of their therapeutics, and ultimately aims to bring their innovative treatments to market.
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Century Therapeutics Inc. is a biotechnology company that aims to develop novel cell therapies targeting various diseases. Their business model focuses on leveraging induced pluripotent stem cell (iPSC) technology to engineer cellular therapies and bring them to market, with a specific emphasis on treating cancer.
Sources:
Phoenix Biotech Acquisition Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Phoenix Biotech Acquisition Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
